Replies to post #130403 on Biotech Values

[mcbio]

Having an indication with a potential relatively near term approval and being able to attract several partners and seemingly an engine capable of producing additional compounds.

Also, don't forget that EXEL already has several other drugs, above and beyond cabo, that they have out-licensed to several big pharma that are being developed (http://www.exelixis.com/pipeline/out-licensed-compounds ).